drug · oligonucleotide
cemdisiran
pre_registrationupdated 6mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
community read0 votes
Oligonucleotide drug with a maximum clinical stage of Phase 3 (across all indications), with 5 investigational indications.
targets
Complement C5 mRNA
all catalysts(0)
nothing on the calendar yet
Trials studying cemdisiran
- phase3A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
- phase3A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
- phase3A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
- phase3A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
- phase3A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
- EP1Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
- —Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
- phase2Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy
News(4)
- Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drugThe go-ahead for Alnylam Pharmaceuticals–partnered Livsayis marks Regeneron’s second new modality this year after the company secured approval for hearing loss gene therapy Otarmeni in April.biospace · 4h ago
- With FDA nod, Regeneron brings an RNAi drug to autoimmune diseaseThe product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.biopharma_dive · 4h ago
- Regeneron enters neurology field as FDA approves siRNA for myasthenia gravisRegeneron’s siRNA therapy cemdisiran has become the second new drug approved by the FDA for myasthenia gravis inside of a week. Now named Livsayis, the therapy was approved by the FDA for ...endpoints · 4h ago
- Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deckRegeneron executives struck an upbeat tone on an investor call Friday as the biotech posted a consensus-beating $5.1 billion in third quarter earnings and CEO Leonard Schleifer touted the company’s…biospace · 20d ago
Data sources
last refreshed 3m ago
Found something off?
comments(0)
5-min edit window · permanent after that